A Study to Assess the Pregnancy Outcome in Women Exposed to Dayvigo® During Pregnancy Compared to an Unexposed Control Population
- Conditions
- First Posted Date
- 2024-12-20
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 861
- Registration Number
- NCT06744673
A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's Disease
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 90
- Registration Number
- NCT06602258
- Locations
- 🇺🇸
Banner Sun Health Research Institute, Sun City, Arizona, United States
🇺🇸Sharp Neurocognitive Research Center at Sharp Mesa Vista Hospital, San Diego, California, United States
🇺🇸University of California at San Francisco/UCSF, San Francisco, California, United States
A Study of E2086 in Healthy Adult Participants
- First Posted Date
- 2024-07-01
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT06481488
- Locations
- 🇺🇸
Parexel International, Glendale, California, United States
A Study to Evaluate the Efficacy, Safety, and Tolerability of E2086 Compared to Placebo and Active Comparator in Adult Participants With Narcolepsy Type 1
- Conditions
- Interventions
- First Posted Date
- 2024-06-17
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT06462404
- Locations
- 🇺🇸
Exalt Clinical Research, Inc., Chula Vista, California, United States
🇺🇸SDS Clinical Trials, Santa Ana, California, United States
🇺🇸PharmaDev Clinical Research, Miami, Florida, United States
A Study of BB-1701 in Previously Treated Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive or HER2-low Unresectable or Metastatic Breast Cancer
- First Posted Date
- 2024-01-03
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 135
- Registration Number
- NCT06188559
- Locations
- 🇺🇸
Northwest Medical Specialties, Puyallup, Washington, United States
🇺🇸Cleveland Clinic - Fairview Hospital - Cancer Center (Moll Cancer Center), Cleveland, Ohio, United States
🇺🇸Cleveland Clinic - Hillcrest Hospital - Hillcrest Cancer Center, Cleveland, Ohio, United States
A Study To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2086 in Healthy Adult and Elderly Participants
- First Posted Date
- 2023-02-27
- Last Posted Date
- 2024-10-02
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 53
- Registration Number
- NCT05745207
- Locations
- 🇺🇸
Worldwide Clinical Trials, San Antonio, Texas, United States
A Study to Assess the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of E2025 in Healthy Participants
- First Posted Date
- 2023-02-14
- Last Posted Date
- 2024-03-25
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT05726851
- Locations
- 🇺🇸
Worldwide Clinical Trials, San Antonio, Texas, United States
A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants
- First Posted Date
- 2022-09-09
- Last Posted Date
- 2023-01-18
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 160
- Registration Number
- NCT05533801
- Locations
- 🇺🇸
Anaheim Clinical Trials, Anaheim, California, United States
A Study to Assess the Safety and Tolerability of E2511 in Healthy Adult and Elderly Participants
- First Posted Date
- 2021-12-07
- Last Posted Date
- 2022-09-09
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 47
- Registration Number
- NCT05147337
- Locations
- 🇺🇸
California Clinical Trials Medical Group, Glendale, California, United States
A Study of Remitoro in Participants With Recurrent or Refractory Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma (All Case Study)
- Conditions
- Interventions
- First Posted Date
- 2021-11-30
- Last Posted Date
- 2023-12-12
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 118
- Registration Number
- NCT05137847
- Locations
- 🇯🇵
Eisai Trial Site 2, Tokyo, Japan
🇯🇵Eisai Trial Site 3, Nagoya, Japan
🇯🇵Eisai Trial Site 1, Osaka, Japan